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1. Introduction 
Homocysteine is a sulphur-containing amino acid, which structurally is closely related to 
the essential amino acids methionine and cysteine. The cellular methylation cycle performs 
the metabolism of methionine and since homocysteine is an intermediate within this cycle, 
the body in this way is provided with all organic homocysteine. The term homocysteine is 
used to define the combined pool of homocysteine, homocystine, and mixed disulfide 
compounds (Fig. 1) even involving homocysteine thiolactone a cyclic form which is often 
found in the plasma of patients with hyperhomocisteinemia.  
 
Fig. 1. Structural formulae of homocysteine 
Homocysteine was first isolated by Butz and du Vigneaud in 1932. However, the relation of 
homocysteine to human disease was first suggested in 1962, in the classical paper of Carson 
and Neil, reporting an elevated homocysteine level in the urine of mentally retarded 
children. Nowadays, it has long been known that homocystinuria—also known as severe 
hyperhomocysteinemia, a genetic disorder in which blood levels of homocysteine are about 
20-fold higher than the normal concentration—is associated with greatly increased risk for 
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premature vascular disease, occlusive cardiovascular disease in early life and childhood, 
leading to incidental strokes or heart attacks in teenagers. It is caused by inherited metabolic 
defects of the homocysteine metabolism, and is therefore positively correlated with a very 
high risk of venous thromboembolism (VTE), (Mudd et al., 1970).  
These observations raised the question whether moderately elevated plasma homocysteine 
concentrations, often called moderate hyperhomocisteinemia, may also cause irritation of 
the blood vessels and are a risk factor for cardiovascular disesase (CVD) in general 
(McCully, 1960). McCully proposed that elevated homocysteine can cause atherosclerotic 
vascular disease (McCully, 1960). Early support for this concept came from a study 
published in 1976 by Wilcken and Wilcken, who reported that, following an oral dose of 
methionine, serum homocysteine levels tended to be higher in patients with premature 
coronary disease than in healthy controls (Wilcken & Wilcken, 1976).  
Mild or moderate hyperhomocysteinemia which occurs in the health population with a 
frequency of 5 to 7 % is often caused by the interaction of environmental factors with mild 
genetic abnormalities of homocysteine metabolism.  
Venous thrombosis was clearly described in patients with mild/moderate homocysteinuria 
and since then, several case-control and prospective studies showed the association with 
increased risk of VTE, (Mudd et al., 1985). Besides, also a large number of retrospective 
studies show that mildly elevated homocysteine levels (mild/moderate 
hyperhomocysteinemia caused by the interaction of envirovmental factors with mild genetic 
abnormalities of homocysteine metabolism) are associated with VTE. Only recently, an 
elevated homocysteine level has also been established as a risk factor for venous thrombosis 
(Moll, 2004). Moreover, in patients with venous thrombosis elevated homocysteine levels 
have attracted considerable interest because homocysteine is an easy to monitor 
thrombophilic marker, and thus can indicate the time and need for measures, to potentially 
reverse the venous thrombosis (Cattaneo, 2006).  
Because of the already high prevalence of (hyper/moderate/mild) homocysteinemia in the 
healthly population and people with disease, this review focusses the attention on (1) the 
relevance of the metabolic pathway of homocysteine, (2) the importance of dietary intake of 
folate, vitamines B6 and B12 and (3) the recommendations to modify life style factors in 
order to prevent, in general, a further homocysteinemia-induced increase of the VTE and 
cardiovascular disease complications. 
2. Homocysteine metabolism 
2.1 Plasma homocysteine 
As mentioned in the introduction homocysteine is a sulfur–containing intermediate in the 
normal metabolism of the essential amino acid methionine, occuring in almost all body cells 
and in general 5 to 10% of the daily synthesized homocysteine (1.2 mmol/day) is transferred 
into the blood through hepatocytes (Weisberg et al., 2003). Besides, proliferating cells secrete 
more homocysteine compared to non-proliferating cells. Although plasma concentrations of 
homocysteine vary widely, on the other hand the intracellular concentrations are preserved 
within a narrow range (Moat et al., 2004). In the plasma, about circa 90% homocysteine is 
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protein-bound, while circa 10% is present as the cysteine mixed disulphide and less than 1% 
is present in the free reduced form. The total plasma level includes the summed amount of 
all the homocysteine forms in the circulation (Hankey & Eikelboom, 1999).  
Normal and abnormal homocysteine levels are set by individual laboratories. Typically, 
considered normal is less than 13 μmol/L, between 13 and 60 μmol/L is considered 
moderately elevated, and higher than 60 to 100 μmol/L is severely elevated (Moll, 2004). 
The total plasma homocysteine concentrations during hyperhomocysteinemia are between 
12 and 30 μmol/L, with gender differences being present. Higher values are measured in 
men, and apparently the presence of estrogen in women determines the plasma 
concentration after the menopause the blood levels of homocysteine of woman approximate 
those in men (Ridker et al., 1999), Table1.  
 
Sex Age Lower limit Upper limit Unit Moderatelly elevated 
Female 12–19 years 3.3 7.2 μmol/L 13-60 μmol/L 
 >60 years 5 12 μmol/L 
Male 12–19 years 4.3 9.9 μmol/L > 11.4 μmol/L 
 >60 years 6 15.3 μmol/L 
Table 1. Blood reference ranges for homocysteine 
The homocysteine levels are measured through a routine blood test, where blood samples 
are collected in EDTA or citrate anticoagulant tubes and should be centrifuged and the 
plasma separated immediately. Ideally, the homocysteine is measured in overnight fasting 
subjects, since high-protein meals will influence the results. Another test, the methionine-
load test measures the homocysteine levels before and after the intake of 100 mg/kg of 
methionine and can be used to diagnose abnormal homocysteine metabolism in people with 
a high risk for cardiovascular disesase, but who have normal homocysteine concentration 
during fasting. This test can be used to make decisions about therapy.   
Homocysteine exists in plasma in a free and a bound form. The determination measures the 
total homocysteine level is the sum of all forms. The commercial methods of determination 
include the transformation of all forms of homocysteine, by means or reduction, into total 
homocysteine, which than is quantified by different methods: gas chromatography, mass 
spectrometry, high pressure liquid chromatography and the most frequently commercial 
methods as florescence polarization immunoassay, chemiluminescence immunoassay, or 
enzyme-linked immunoassay,  used on different analyzers. 
Results obtained with different methods are often not very com-parable each other because 
of considerable inter-method and inter-laboratory variability. Reported approaches for the 
measurement of plasma tHcys include: ion-exchange chromatography, immunoassays 
(ﬂuorescence polarization immunoassay, FPIA, or chemiluminescence immunoassay, ICL,or 
enzyme-linked immunoassay, EIA), HPLC (with photometric, ﬂuorescence or 
electrochemical detection),capillary electrophoresis  with photometricor laser ﬂuorescence 
detec- tion), GC–MS,and LC–ESI-MS/MS. Many of  them have signiﬁcant disadvantages, 
including derivatization protocols, are expensive and time-consuming. Compared with the 
above mentioned, LC–ESI-MS/MS seems to be the most suitable method because of its 
inherent accuracy, high sensitivity, speciﬁcity and high  through put  for t Hcys analysis. 
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2.2 Role of B vitamins and enzymes 
B vitamins function as coenzymes in the synthesis of purines and thymidylate during 
normal DNA synthesis. Diminished levels of these vitamins may result in 
misincorporation of uracil into DNA, leading to chromosome breaks and disruption of 
DNA repair and both, folate and vitamin B12 levels are involved in DNA methylation. 
Deficient folate and vitamin B12 levels can reduce the availability of S-
adenosylmethionine, the universal methyl donor, for DNA methylation and may thereby 
influence gene expression (Blount et al., 1997).  
Some people have elevated homocysteine levels due to an unbalanced diet with suboptimal 
intake of B vitamins (B6, B12 and folate), which act as coenzymes in the metabolism of 
homocysteine (de Bree et al., 1997, Stanger et al., 2003). Several studies have found that high 
blood levels of B vitamins influence the integrity and function of DNA, and, correlate with a 
low concentration of homocysteine, while folate depletion has been found to change DNA 
methylation and DNA synthesis in both animal and human studies. 
B vitamines are very important in the transformation of homocysteine in methionine and are 
cofactors to three important enzymes directly involved in the homocysteine metabolism: (1) 
methionine synthase (MS), (2) methylenetetrahydrofolatereductase (MTHFR) and (3) 
cystathione ǃ-synthase (CBS).  
Therefore, deficiencies of folate and vitamin B12 and reduced activity of the involved 
metabolic enzymes will inhibit the breakdown of homocysteine, leading to an accumulation 
of the intracellular homocysteine, followed by rapid excretion to the circulation and 
eventually increased plasma levels (Silaste et al., 2001).  
Via the trans-sulfuration pathway homocysteine is converted into cystathionine to form 
cysteine by cystathionine-ß-synthase, with vitamin B6 as a co-factor. Another pathway of 
homocysteine metabolism is the re-methylation pathway, which is connected with the folate 
metabolic pathway (Fig. 2). It involves the transfer of a methyl group from 5-methyl-
tetrahydrofolate to homocysteine to form methionine, and eventually S-
adenosylmethionine. The methyl transfer from 5-methyl tetrahydrofolate to homocysteine is 
catalyzed by methionine-synthase, and requires vitamin B12 as a cofactor. Important to 
notice is that S-adenosylmethionine is the universal methyl donor for methylation reactions. 
The resulting tetrahydrofolate transfers into the 5,10-methyltetrahydrofolate with the 
enzyme 5,10-methyltetrahydrofolate reductase (MTHFR) and then into the 5-
methyltetrahydrofolate 5-MTHF, (Fodinger et al., 2000). The cellular availability of 5-MTHF 
may be of great importance in regulating cellular effects of homocysteine related to cell 
growth.  
The methyl group of 5-MTHF is transported to vitamin B12 linked to the enzyme 
homocysteine–methyl-transferase to yield methylcobalamin-enzyme. This complex adds the 
methyl group to homocysteine to form methionine (Pietrzik & Brönstrup, 1998). 
Therefore, deficiencies of folate and vitamin B12 and reduced activity of the involved 
metabolic enzymes will inhibit the breakdown of homocysteine, which will lead to an 
increase of the intracellular homocysteine concentration (Silaste et al., 2001). 
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Fig. 2. Homocysteine metabolism 
S-adenosylhomocysteine is formed during S-adenosylmethionine-dependent methylation 
reactions, and the hydrolysis of S-adenosylhomocysteine results in homocysteine. 
Homocysteine may be remethylated to form methionine by a folate-dependent reaction that 
is catalyzed by methionine synthase, a vitamin B12-dependent enzyme. Alternately, 
homocysteine may be metabolized to cysteine in reactions catalyzed by two vitamin B6-
dependent enzymes.  
3. Causes of hyperhomocysteinemia  
3.1 Genetic deffects 
Elevation in plasma homocysteine are typically caused either by genetic defects in the 
enzymes involved in homocysteine metabolism or by nutritional deficiencies in vitamin 
cofactors. Homocysteinuria and severe hyperhomocystenemia are caused by rare inborn 
errors of metabolism resulting in marked elevations of plasma and urine homocysteine 
concentrations. 
Most studies refer to changes in the cystathionine ǃ-synthase gene or in the GCT gene (Ǆ 
cystathionase), both coding the trans-sulfuration pathway (references). Further, mutations 
do occur in the genes coding for the enzymes involved. Cystathionine ǃ-synthase (CBS) 
deficiency is the most common genetic cause of severe hyperhomocysteinemia. As first 
shown in a study by Carey and colleagues as early as 1968, the homozygous form of this 
disease — congenital homocystinuria — can be associated with hyperhomocysteinemia, and 
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in these homozygotes there is a frequent development of atherothrombotic complications 
during young adulthood, which often are fatal. Mudd and colleagues estimated that 
approximately 50 percent of untreated homocystinuria patients will have a thromboembolic 
event before the age of 30 and that the disease-related mortality is approximately 20 percent 
(Mudd et al., 1970).  
Other abnormalities of the remethylation cycle that are associated with 
hyperhomocysteinemia include genetic methionine synthase deficiency and genetic 
disorders of vitamin B12 metabolism both impairing methionine synthase activity.  
Genetic mutations in MTHFR are the most commonly known inherited risk factor for 
elevated homocysteine levels. To have any detrimental effect, mutations must be present in 
both copies of a person's MTHFR genes (Varga et al., 2005). (1) A point mutation in the 
coding region for the 5,10-MTHFR binding site (C677T), leading to the substitution of an 
alanine to a valine effectively increases homocysteine levels increase and decreases 
methionine levels or (2) A1298C another common point mutation of the MTHFR gene, both 
affect the enzyme activity catalyzing the vitamin B12–dependent remethylation of 
homocysteine to methionine. C677T homozygotes carry the double TT (thermolabile) allele 
of the enzyme MTHFR gene of which the enzyme activity is reduced to 35% of the normal 
(Schriver et al., 1995), and having an average homocysteine level of 19.7 µM. In CT 
heterocygotes this is 10.3 µM, while for CC unaffected this is 10.0 µM. Further, data show 
that people with C677T TT have 21% increased risk of ischemic heart disease; in those with 
CT the risk is increased by only 6% (Dinesh -K, 2004).  
Aproximally 10% to 20% of Caucasians carry the TT allele, whereas the remaining 80% -
90% carry either the CT or CC alleles. Black subjects have a very low frequency of carring 
the TT allele. The C677T mutation does have different regional incidences in Europe 
where the German and Italian populations show different incidences of 24.5% and 43.8% 
respectively. 
3.2 Other disease states 
Hyperhomocysteinemia occurrs in a wide range of unrelated diseases as depicted in Table 1.  
Over the past 15 years, there has been an explosion in the number of scientific articles 
describing an association between homocysteine and vascular disease. 
Hyperhomocysteinemia has been linked to an increased risk of cardiac events; sudden 
death; stroke; coronary- carotid- cerebral- and peripheral-arterial diseases. It is also 
implicated in transplant coronary artery disease and essential hypertension (Dinesh, 
2004). In general, retrospective analyses show that for every 4 µM rise in homocysteine 
levels, the relative risk for cardio vascular disease increases by 1.3 to 1.4 (Nygard et al. 
1997a). Data obtained from (COMAC-European concerted Action Project (Graham et al., 
1997), which studied patients with vascular disease and control subjects, confirmed that 
homocysteine levels more than 12 µM increased the risk for all types of atherotrombotic 
vascular disease. So, after a thorough review of the available literature, 
hyperhomocysteinemia should be considered an independent risk factor for 
cardiovascular disease.  
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Aging Heart conditions 
Alzheimers disease Mental retardation 
Anaemias Migraines 
Angina Miscarriages 
Arthritis Osteoporosis 
Artheriosclerosis Parkinson's disease 
Auto-immune diseases Polycystic ovary disease 
Birth defects Pregnancy complications 
Cancers Psoriasis 
Cholesterol - high Rheumatoid arthritis 
Chronic fatigue Schizophrenia 
Coeliac disease Strokes 
Chrohn's disease Thyroid disorders 
Depression Ulcerative colitis 
Diabetes Epilepsy 
  
 
Table 2. Common diseases associated with high homocysteine levels (Hultberg et al., 1993; 
Pettersson et al., 1998; Bolander-Gouaille, 2001; Hultberg, 1993).  
3.3 Lifestyle factors 
From a public health viewpoint, it is important to identify modifiable factors that influence 
the plasma homocysteine concentrations. The next lifestyle factors may have an effect on 
plasma homocysteine concentration (Bolander-Gouaille, 2001): 
3.3.1 Smoking 
Smoking is associated with vascular disease and other complications related to 
homocysteine (Bolander-Gouaille, 2001). The number of cigarettes smoked a day was one of 
the strongest determinants of homocysteine levels (Nygard et al., 1995). In women, the 
increase of plasma homocysteine levels was about 1% per each cigarette smoked, and in 
men about 0.5%. The mechanisms by which smoking increases the homocysteine levels may 
be manifold, however there is some experimental evidence that nicotine directly affects the 
methylation reactions. Besides, in smokers catabolism of folate has been suggested(Godin & 
Crooks, 1986).  
3.3.2 High alcohol intake 
High alcohol consumption is often associated with gastrointestinal disturbances, which may 
result in decrease absorption of vitamins (the most important is folic acid), thus contributing 
to elevated homocysteine levels. Alcohol has also been reported to inhibit methionine 
synthase (MS), to decrease hepatic uptake and increase excretion, mainly via urine (Barak et 
al., 1993). The decreased concentration of serum folic acid may occur in 80% of alcohol 
abusers and this can lead to serious clinical consequences.  
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3.3.3 Coffee consumption 
Coffee consumption has been associated with several risk factors for coronary heart disease, 
including plasma total homocysteine and reduced B vitamin concentrations (Ulvike et al., 
2008). Coffee drinking is associated with smoking and low intake of fruit and vegetables. 
Tea consumption, in contrast, was associated with lower homocysteine levels (Nygard et al., 
1997b).  
3.3.4 Inadequate nutrition 
B vitamins have been suggested to play a critical role to maintain low homocysteine levels 
(Silaste et al., 2001). A diet poor in fresh fruit and vegetables or strict vegeterians may 
develop nutritional vitamin B12 deficiency (Miller et al., 1991). This is particulary serious in 
pregnancy, as the mother may not be able to supply the fetus with sufficient vitamin B12. 
Also modern food processing may destroy essential vitamins and it has recently been shown 
that microwave heating may destroy as much as 30 % of the vitamin B12 content in food 
(Watanabe et al., 1998). Prolonged heating may also destroy folate and vitamin B6. Besides, 
healthly subjects eating fish more than 3 times a week had lower homocysteine levels than 
those eating fish less than one a month.  
3.3.5 Physical activity 
Physical activity plays an important role in our life, since it is the cheapest way of 
strengthening our health and reduces the risk of developing cardiovascular diseases. It has 
been confirmed that physical activity decreases the concentrations of total plasma 
homocysteine and thus the probability of developing a cardiovascular disease in healthy 
and already sick people. In the study called Bed rest “The influence of simulated 
weightlessness upon the human organism” performed in 2006, 2007 and 2008 at the 
Valdoltra Orthopaedic Hospital, Slovenia, in which young male participants (age 24-30 
years) rested in horizontal position for 35 days, a statistically increased homocysteine 
concentration was documented (Plazar et al., 2008). The diet composition and the energy 
intake were daily supervised and monitored by a dietician. Volunteers were non-smokers, 
non-alcoholics, without history of cardiovascular and neuromuscular disorders. Several 
studies indicate physical activity as an independent lifestyle factor connected with lower 
homocysteine concentration. Besides, exercise is associated with a reduction in plasma 
fibrinogen concentrations, and with increasing activity levels of exercise a reduction in 
homocysteine was observed. So, this prolonged bed rest study confirms that increased levels 
of homocysteine in blood, negatively influences the cardiovascular system. Although, the 
precise mechanism is not well understood, similar consequences can result from prolonged 
physical inactivity in everyday life. 
3.3.6 Age related factors 
Many studies have shown that hyperhomocysteinemia increases with age (Pennypacker et 
al., 1992). This is connected with inadequate nutrition, the changes in gastrointestinal 
function, B vitamins deficiency, enzyme defects, a higher occurance of the C677T mutation 
and numerous age-related physiological factors.  
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MOST COMMON RISK FACTORS   
Inherited 
 CBS deficiency 
 MTHFR deficiency 
 MS deficiency 
 Being male  
Aquired 
 Aged 40 +   
 Deficients of folate, vitamin B6 and B12 
 Post menopausal status   
 Drinking alcohol   
 Smoking   
 Often angry or suppress anger   
 Physical inactivity  / sedentary life-style 
 Drinking caffeinated drinks - coffee, tea, coke   
 Being pregnant   
 Being strict vegetarian   
 High fat/protein diet intake   
 High diet salt intake   
 Hypothyroidism   
 Chronic kidney problems   
 Use drugs:  e.g.: phenytoin, carbamazepine, methotrexate, aminoglutethimide   
 Suffering from chronic illnesses   
 Digestive problems, auto-immune diseases, asthma, eczema, arthritis, 
osteoporosis,  ulcers, diabetes, heart conditions, high blood pressure, thrombosis, cancer  
Table 3. Common risk factors inducing mild hyperhomocysteinemia  
4. Venous thromoembolism and hyperhomocysteinemia 
It has been recognized, since the first description of hyperhomocysteinemia, that arterial 
and venous thrombosis are common in these patients. Patients with homocysteinuria 
suffered of thrombotic events, cerebrovascular occlusions, deep vein thromboses, 
myocardial infarctions and peripheral vascular thromboses (Mudd et al., 1985) of which a 
quarter of all thrombotic events occured before the age of 16 and half before the age of 28, 
much earlier in life than would normally be expected for these types of events. Further, 
patients with CBS deficiency-induced homocysteinuria have high levels of plasma 
homocysteine (Carey et al., 1968). Interest in the hyperhomocysteinemia condition 
increased when a large number of studies (mainly retrospective) showed that also mildly 
elevated homocysteine levels are associated with venous thromboembolism (VTE), 
thrombotic stroke, and peripheral vascular disease (Wilcken & Wilcken, 1976, Mudd et al., 
1985, Moll, 2004).  
To conclude, mild hyperhomocysteinemia can be induced by a variety of risk factors of 
which the most common genetic factors are heterozygous CBS gene defects and 
polymorphism in the MTHFR gene at position 677, while as well numerous aquired 
conditions might be involved (Table 3). 
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Independent from other factors hyperhomocysteinemia is associated with a 4.8 fold 
increased risk for VTE (Köktürk et al., 2010).  
4.1 Mechanisms for thrombosis in hyperhomocysteinemia 
Homocysteine impairs intrinsic thrombolysis and endothelium function (Dalton et al., 1997; 
Nishio & Watanabe; 1997). Studies of cultured cells in vitro indicate that homocysteine has 
prothrombotic effects on the endothelium and vascular smooth muscle. In vitro test results 
show that endothelial cells are damaged by moderate hyperhomocysteinemia mainly 
because of the impact of hydrogen peroxide (Hultberg et al., 1997).  
Homocysteine though oxidative stress, probably directly damages endothelial cells by: (1) 
the direct oxidation of low density lipoproteins (2) its cytoplasmic oxidation products like 
homocystine, mixed disulfides and homocysteine thiolactone, which lead to the 
development of reactive oxidative species ROS such as hydrogen peroxide, superoxide 
anion and hydroxide radical (3) acceleration of fibrin and collagen accumulation in 
endothelial cells and smooth muscle cells, stimulating their proliferation and thus changes 
the vessel wall leading to or at least accelerating thrombus and vascular disease. 
The metabolism of homocysteine is connected with the cellular level of S-adenosyl 
methionine (SAM) which is a co-substrate involved in methyl group transfers of both the 
transsulfuration and remethylation metabolic pathways (Fig.2) by the enzyme 
methyltransferase. At the same time, SAM is the methyl group donor in the methylation of 
DNA, proteins, phospholipids and biogenic amines. Therefore, the methyltransferase 
function depends on the cell concentration of both SAM and S-adenosyl homocysteine 
(SAH). Effectively, high cellular homocysteine levels inhibit vital methylation reactions, 
affecting the maintenance of the DNA structure; without repair mutations can occur and the 
structure can collapse. The close connection of homocysteine metabolism with methyl 
transfer reactions imply, that changed methyl transfer reactions are responsible for some of 
the effects of altered vessel function during hyperhomocysteinemia.  
It is very likely that the mechanisms by which homocysteine changes vessel function are 
oxidative stress and alterations of cell methylation (Lentz, 1998). The proposed pathogenetic 
mechanisms which associate hyperhomocysteinemia and vascular injury are oxidative 
damage of the endothelium through suppression of the vasodilator nitric oxide, increasing 
the level of asymmetric dimethylarginine, impairing methylation, proliferation of vascular 
smooth muscle, and disruption of the normal procoagulant balance in favor of thrombosis.  
4.2 Homocysteine and thrombosis in malignancies, renal failure, retina veins 
4.2.1 Malignancies and VTE 
More recently, increased plasma homocysteine concentration has been postulated as a risk 
factor for cancer and even as a novel tumor marker (Sun et al., 2002). Patients with 
malignancies often have an increased risk of VTE disease and as such being the second most 
common cause of death in cancer patients, second to the primary disease itself (Rickles et al., 
1992). In 1865 Trousseau described hypercoagulability and increasing risk of »spontaneous 
coagulation« in patients with cancer (Trousseau, 1865). Nowadays, it is established that 
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breast, pancreas, and gastrointestinal cancers are associated with a higher incidence of 
thrombosis. With more advanced stages of cancer there is a lower overall survival rate, but, 
also a greater risk of venous thromboembolism, additionally influencing the survival of 
patients.  
The associated pathophysiology of VTE and malignancies has not been precisely defined. 
However, it has been reported that cancer patients show increased levels of several pro-
coagulant factors (Falanga et al., 1993). It is well established that women with advanced 
breast cancer show hyperhomocysteinemia, which explains the hight rate of venous 
thrombosis in women with metastatic breast malignancy (Smith et al., 2008). Other 
established contributors to the VTE increased risk are: chemotherapy, hormonal adjuvant 
therapy, surgery, central venous catheters, immobility and inherited thrombophilia, with 
the notion that oncological therapies do influence the immunological response.  
4.2.2 Renal failure and VTE 
Under physiological conditions, non-protein bound homocysteine is subjected to glomerular 
filtration, and almost completely reabsorbed in the tubuli and oxidatively catabolized to 
carbon dioxide and sulphate in the kidney cells. The clearance is markedly reduced in renal 
failure with a strong, positive correlation between homocysteine levels, serum creatinine 
and the glomerular filtration rate (Hultberg et al., 1993). Hyperhomocysteinemia in patients 
with chronic renal failure induces an oxidative stress to the vascular endothelium, causing a 
failure in vasodilatation and an impairment of antithrombotic properties. In patients with 
end-stage renal disease (ESRD) the prevalence of hyperhomocysteinemia is 85-100% and of 
the fifty-nine ESRD patients undergoing hemodialysis treatment with supplemented B 
vitamines it was concluded that the MTHFR C677T mutation is an important genetic 
determinant of elevated plasma homocysteine concentration level.  
4.2.3 Retinal Vein occlusion 
Several studies have examined the relationship between hyperhomocysteinemia and retinal 
vein occlusion, a condition affecting approximately five out of 1000 of the general 
population over 64 years of age (David et al., 1988). The association between retinal vein 
occlusion, hyperhomocysteinemia and thermolabile MTHFR was confirmed (Janssen et al., 
2005).  
4.2.4 Homocysteine and thrombosis in children 
Venous thrombosis in children occurs at a much lower frequency than in adults and the 
events are usually provoked by acquired risk factors like sepsis, cancer and central venous 
catheters. The association of VTE and hyperhomocysteinemia in children has been 
confirmed in two case control studies (Koch et al., 1999; Kosch et al., 2004).  
4.2.5 Hyperhomocysteinemia and pregnancy 
Hyperhomocysteinemia during pregnancy, which is a consequence of perturbations in 
methionine and/or the folate metabolism, has been implicated in adverse outcomes such as 
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neural tube defects, preeclampsia, spontaneous abortion, and premature delivery 
(Dasarathy et al., 2010). This is pertinent as it is believed that placental thrombosis may 
contribute to the pathogenesis of these conditions (Gatt & Makris, 2007).  
5. Treatment of hyperhomocysteinemia 
The treatment of hyperhomocysteinemia varies with the underlying cause.  
In the case of deficiency of one or more vitamins involved in homocysteine metabolism, 
blood levels of this amino acid are often elevated well above those observed in the healthy 
population. Treatment of hyperhomocysteinemia includes supplementation with mostly 
pharmacological doses of one or more of the relevant B vitamins and is generally effective 
in reducing homocysteine concentrations and delays atherosclerotic and thrombotic 
events.  
The negative impact of particular genotypes on homocysteine levels can partly be 
compensated by folate intake and is, even in smaller part, dependent on several other 
variables that affect homocysteine levels (see Table 2). For example, if persons have 
balanced diet with optimal intake of B6 and B12 vitamins and folates it seems that the C677T 
mutation and the subsequent reduced activity of the enzyme MTHFR do not connect with 
hyperhomocysteinemia (Schriver et al., 1995; Silaste et al., 2001). Besides, folic acid 
supplemetation reduces the plasma homocysteine concentration in all three genotypes (TT, 
CT and CC) of the MTHFR C677T mutation (Meshkin & Blum, 2007).  
This scientific evidence suggests that the MTHFR C677T genetic mutation influences folate 
metabolism, leading to the conclusion that dietary intake of a standard dosage of folate may 
be insufficient for half to two-thirds of the population with this mutation (Meshkin & Blum, 
2007).  
In the case of CBS deficiency, the enzyme activity can effectively be enhanced by treatment 
with large doses of vitamin B6.  
A combination of all three relevant coenzymes to treat milder forms of 
hyperhomocysteinemia resulted in a clear 50% reduction of plasma homocysteine levels. 
However, given alone, only folic acid was able to induce similar reductions, whereas 
vitamin B 12 was little effective and vitamin B6 failed to show an effect (Perry et al., 1968, 
Ubbink et al., 1993; Ubbink et al., 1994).  
Many countries have implemented mandatory folic acid fortification of flour and grain 
products to reduce the risk of various diseases. Besides, individuals can find a good source 
of folate in fruits and vegetables (especially green leafy vegetables).  
6. Who should be tested for MTHFR mutations and homocysteine levels 
For individuals with unexplained arterial or venous blood clots and unexplained 
atherosclerosis it seems appropiate having blood homocysteine levels checked. One can also 
argue that everybody with atherosclerosis, patients with CVD, heart attacks, or strokes, 
should have their blood checked for homocysteine levels. All this in order to prevent further 
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damage. At this time, no clear medical indication exists for women with a history of 
recurrent pregnancy loss, preeclampsia, placental abruption, and/or small-for-age babies to 
have homocysteine levels checked, although appropiate clinical research should come with 
more evidence for this.  
As with homocysteine, no official guidelines exist as to who should be tested for MTHFR. In 
the absence of elevated homocysteine levels, MTHFR mutations appear to have no clinical 
relevance in regard to thrombosis and atherosclerosis. However, in case of elevated 
homocysteine levels of MTHFR patients the risk for venous thromoembolism increases 
dramatically. Since treatment can be relatively easy according to diet, one could argue that 
there is indication to perform MTHFR genetic testing after the homocysteine test shows 
elevated levels (Varga et al., 2005).  
7. Conclusion 
Elevated homocysteine concentration has been identified as an independent risk factor for 
premature cardiovascular disease.  
Results of multiple prospective and case control studies have shown that patients with a 
moderately elevated plasma homocysteine concentration are more likely to develop venous 
and arterial thrombosis compared to the control population. Homocysteine seems to 
promote atherothrombosis by a variety of mechanisms. The precise pathogenic mechanism 
remains to be confirmed and it is not yet clear whether homocysteine itself or a related 
metabolite or a cofactor is primarily responsible for the atherothrombogenic effects of 
hyperhomocysteinemia. However, recent studies indicate that lowering an elevated 
homocysteine level does decrease the risk of atherosclerosis and blood clots. Until this issue 
has been more clearly defined, it appears prudent to make an effort to try to lower one’s 
homocysteine levels through supplementation with B vitamins, which is an efficient and 
safe way to reduce an elevated homocysteine levels.  
The MTHFR mutations appear to be medically irrelevant, as long as an individual’s 
homocysteine level is normal. Therefore, it should be first the homocysteine level, not the 
MTHFR genetic status, to be tested in patients with or at risk for blood clots, atherosclerosis, 
or pregnancy complications.  
It is well estabilished that healthly lifestyle lowers homocysteine concentrations. So the 
most important in everyday life is awareness that the level of homocysteine in blood is 
strongly influenced by several lifestyle factors such as nutrition, stress, smoking 
cigarettes, alcohol consumption, or physical inactivity. And therefore, exercise is a 
commonly recommended lifestyle intervention for individuals at risk for, or diagnosed 
with, cardio vascular disease. More specifically, we suggest that exercise, mild in aged 
people, but especially heavy physical activity, exerts its most favorable effect in subjects 
with hyperhomocysteinemia.  
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